Skip to content
About us
Overview
Our founders
Careers
Our pipeline
Development pipeline
Netazepide
Background
Studies
Further studies
Ceclazepide
TR4
TR8
Our publications
Contact us
Our pipeline
The original aim of Trio was to develop netazepide, a gastrin/CCK
2
receptor antagonist, for clinical use. Trio has since grown and now has three other molecules: ceclazepide, TR4, and TR8.
Our pipeline
myarzi1
2019-09-25T12:24:00+00:00
Netazepide
Ceclazepide
TR4
TR8
